| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA829: Upadacitinib for treating active ankylosing spondylitis |
|
Medicine details |
|
| Medicine name | upadacitinib (Rinvoq®) |
| Formulation | 15 mg prolonged release tablets |
| Reference number | 4455 |
| Indication | Treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy |
| Company | AbbVie Ltd |
| BNF chapter | Musculoskeletal & joint diseases |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 24/05/2021 |
| NICE guidance | TA829: Upadacitinib for treating active ankylosing spondylitis |
| Commercial arrangement | PAS |